From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Opsonins are proteins of the innate and adaptive immune system that facilitate phagocytosis and cell lysis by “marking” antigens.[1] Opsonization, then, is the modification of antigens by opsonins to make them more accessible to phagocytic cells and other immune cells.[1] Opsonins bind to antigen and are recognized by receptors on immune cells.[1]

Opsonins of the innate immune system largely comprise complement proteins, though interaction between complement proteins and antibodies constitutes an adaptive immune response.[2] Antibodies independently serve as opsonic molecules in the adaptive response.[3]

Opsonin proteins bind to surface molecules or membranes of pathogens, and receptors on phagocytic cells bind to opsonins to initiate phagocytosis.[2][3][4] Opsonization helps clear pathogens, dying cells, and marks diseased cells.[1]


All cell membranes have negative charges (zeta potential) which makes it difficult for two cells to come close together. When opsonins bind to their targets they boost the kinetics of phagocytosis by favoring interaction between the opsonin and cell surface receptors on immune cells.[5] This overrides the negative charges from cell membranes. This principle holds true for clearance of pathogens as well as dead or dying self cells.



Antibody-mediated opsonization. FcR on phagocytic cells recognize the Fc region of the antibody.

Antibodies are synthesized by B cells and are secreted in response to recognition of specific antigenic epitopes, and bind only to specific epitopes (regions) on an antigen.[3] They comprise the adaptive opsonization pathway, and are composed of two fragments: the antigen binding region (Fab region) and the fragment crystallizable region (Fc region).[3] The Fab region is able to bind to a specific epitope on an antigen, such as a specific region of a bacterial surface protein.[3] The Fc region of IgG is recognized by the Fc Receptor (FcR) on natural killer cells and other effector cells; the binding of IgG to antigen causes a conformational change that allows FcR to bind the Fc region and initiate attack on the pathogen through the release of lytic products.[3] Antibody may also tag tumor cells or virally infected cells, with NK cells responding via the FcR; this process is known as antibody-dependent cellular cytotoxicity (ADCC).[3]

Both IgM and IgG undergo conformational change upon binding antigen that allows complement protein C1q to associate with the Fc region of the antibody.[4] C1q association eventually leads to the recruitment of complement C4b and C3b, both of which are recognized by complement receptor 1, 3, and 4 (CR1, CR3, CR4), which are present on most phagocytes.[4] In this way, the complement system participates in the adaptive immune response.

Opsonization by C3b. CR1 recognizes C3b deposited on antigen

C3d, a cleavage product of C3, recognizes pathogen-associated molecular patterns (PAMPs) and can opsonize molecules to the CR2 receptor on B cells.[4] This lowers the threshold of interaction required for B cell activation via the B cell receptor, and aids in the activation of the adaptive response.[4]


The complement system, independently of the adaptive immune response, is able to opsonize pathogen before adaptive immunity may even be required.[2][4] Complement proteins involved in innate opsonization include C4b, C3b and iC3b.[6] In the alternative pathway of complement activation, circulating C3b is deposited directly onto antigens with particular PAMPs, such as lipopolysaccharides on gram-negative bacteria.[6] C3b is recognized by CR1 on phagocytes. iC3b attaches to apoptotic cells and bodies and facilitates clearance of dead cells and remnants without initiating inflammatory pathways, through interaction with CR3 and CR4 on phagocytes.[2]

Mannose-binding lectins, or ficolins, along with pentraxins and collectins are able to recognize certain types of carbohydrates that are expressed on the cell membranes of bacteria, fungi, viruses, and parasites, and can act as opsonin by activating the complement system and phagocytic cells.[4][6]


Apoptotic cells[edit]

Apoptosis is related to low tissue inflammation. A number of opsonins play a role in marking apoptotic cells for phagocytosis without a pro-inflammatory response.[7]

Members of the pentraxin family can bind to apoptotic cell membrane components like phosphatidylcholine (PC) and phosphatidylethanolamine (PE). IgM antibodies also bind to PC. Collectin molecules such as mannose-binding lectin (MBL), surfactant protein A (SP-A), and SP-D interact with unknown ligands on apoptotic cell membranes. When bound to the appropriate ligand these molecules interact with phagocyte receptors, enhancing phagocytosis of the marked cell.[5]

C1q is capable of binding directly to apoptotic cells. It can also indirectly bind to apoptotic cells via intermediates like IgM autoantibodies, MBL, and pentraxins. In both cases C1q activates complement, resulting in the cells being marked for phagocytosis by C3b and C4b. C1q is an important contributor to the clearance of apoptotic cells and debris. This process usually occurs in late apoptotic cells.[5]

Opsonization of apoptotic cells occurs by different mechanisms in a tissue-dependent pattern. For example, while C1q is necessary for proper apoptotic cell clearance in the peritoneal cavity, it is not important in the lungs where SP-D plays an important role.[5]


As part of the late stage adaptive immune response, pathogens and other particles are marked by IgG antibodies. These antibodies interact with Fc receptors on macrophages and neutrophils resulting in phagocytosis.[8] The C1 complement complex can also interact with the Fc region of IgG and IgM immune complexes activating the classical complement pathway and marking the antigen with C3b. C3b can spontaneously bind to pathogen surfaces through the alternative complement pathway. Furthermore, pentraxins can directly bind to C1q from the C1 complex.[9]

SP-A opsonizes a number of bacterial and viral pathogens for clearance by lung alveolar macrophages.[7]

See also[edit]


  1. ^ a b c d Punt J, Stranford SA, Jones PP, Owen JA (2019). Kuby immunology (Eighth ed.). New York. ISBN 978-1-4641-8978-4. OCLC 1002672752.
  2. ^ a b c d Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT (2015). "Complement System Part II: Role in Immunity". Frontiers in Immunology. 6: 257. doi:10.3389/fimmu.2015.00257. PMC 4443744. PMID 26074922.
  3. ^ a b c d e f g Chiu ML, Goulet DR, Teplyakov A, Gilliland GL (December 2019). "Antibody Structure and Function: The Basis for Engineering Therapeutics". Antibodies. 8 (4): 55. doi:10.3390/antib8040055. PMC 6963682. PMID 31816964.
  4. ^ a b c d e f g Varela JC, Tomlinson S (June 2015). "Complement: an overview for the clinician". Hematology/Oncology Clinics of North America. 29 (3): 409–27. doi:10.1016/j.hoc.2015.02.001. PMC 4456616. PMID 26043382.
  5. ^ a b c d Roos A, Xu W, Castellano G, Nauta AJ, Garred P, Daha MR, van Kooten C (April 2004). "Mini-review: A pivotal role for innate immunity in the clearance of apoptotic cells". European Journal of Immunology. 34 (4): 921–9. doi:10.1002/eji.200424904. PMID 15048702. S2CID 22966937.
  6. ^ a b c Ricklin D, Hajishengallis G, Yang K, Lambris JD (September 2010). "Complement: a key system for immune surveillance and homeostasis". Nature Immunology. 11 (9): 785–97. doi:10.1038/ni.1923. PMC 2924908. PMID 20720586.
  7. ^ a b Litvack ML, Palaniyar N (June 2010). "Review: Soluble innate immune pattern-recognition proteins for clearing dying cells and cellular components: implications on exacerbating or resolving inflammation". Innate Immunity. 16 (3): 191–200. doi:10.1177/1753425910369271. PMID 20529971. S2CID 8344490.
  8. ^ Zhang Y, Hoppe AD, Swanson JA (November 2010). "Coordination of Fc receptor signaling regulates cellular commitment to phagocytosis". Proceedings of the National Academy of Sciences of the United States of America. 107 (45): 19332–7. Bibcode:2010PNAS..10719332Z. doi:10.1073/pnas.1008248107. PMC 2984174. PMID 20974965.
  9. ^ Sarma JV, Ward PA (January 2011). "The complement system". Cell and Tissue Research. 343 (1): 227–35. doi:10.1007/s00441-010-1034-0. PMC 3097465. PMID 20838815.

External links[edit]